Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Vitamin d and other micronutrients influence prognosis of patients with non-Hodgkin lymphoma (NHL)

Martin Hajek, Marek Trneny, Samuel Hricko, Petra Blahovcova, Miroslav Tomiska, Dalibor Valik, Natasa Kopalova, Andrea Janikova

Blood (2025) 146 (Supplement 1): 7089.

https://doi.org/10.1182/blood-2025-7089

Published: 2025

Journal Articles

Bulky disease and/or very high LDH define a high-risk LBCL subgroup within IPI 1–2, but only in younger patients

Blood (2025) 146 (Supplement 1): 470.

https://doi.org/10.1182/blood-2025-470

Published: 2025

Journal Articles

Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2025-2741

Published: 2025

Journal Articles

Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data

Blood (2025) 146 (Supplement 1): 1834.

https://doi.org/10.1182/blood-2025-1834

Published: 2025

Journal Articles

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2025-4516

Published: 2025

Journal Articles

Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort

Blood (2025) 146 (Supplement 1): 3676.

https://doi.org/10.1182/blood-2025-3676

Published: 2025

Journal Articles

FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis

Blood (2025) 146 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2025-1826

Published: 2025

Journal Articles

Impact of primary CNS prophylaxis in high CNS-IPI DLBCL: Analysis from the czech national lymphoma registry

Samuel Hricko, Magdalena Klanova, Prokop Vodicka, Michal Masar, Petra Blahovcova, Jitka Dlouha, Martin Hajek, Marek Trneny, Andrea Janikova

Blood (2025) 146 (Supplement 1): 8019.

https://doi.org/10.1182/blood-2025-8019

Published: 2025

Journal Articles

Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP

Blood (2025) 146 (Supplement 1): 5448.

https://doi.org/10.1182/blood-2025-5448

Published: 2025

Journal Articles

Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis

Blood (2025) 146 (Supplement 1): 3664.

https://doi.org/10.1182/blood-2025-3664

Published: 2025

Journal Articles

Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study

Blood (2025) 146 (Supplement 1): 898.

https://doi.org/10.1182/blood-2025-898

Published: 2025

Journal Articles

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

Blood (2025) 146 (Supplement 1): 786.

https://doi.org/10.1182/blood-2025-786

Published: 2025

Journal Articles

The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Andrea Hruskova, Heidi Mocikova, Juraj Duras, Katerina Steinerova, Alice Sykorova, Michal Masar, Jitka Dlouha, Petra Blahovcova, Marek Trneny

Blood (2024) 144 (Supplement 1): 1697.

https://doi.org/10.1182/blood-2024-208416

Published: 2024

Journal Articles

Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?

Liliana Tuskova, Diana Maláriková, Katerina Benesova, Eva Konirova, Kamila Polgarova, Petra Blahovcova, Jana Salkova, Marek Trněný, Pavel Klener

Blood (2024) 144 (Supplement 1): 3012.

https://doi.org/10.1182/blood-2024-198865

Published: 2024

Journal Articles

PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Veronika Hanackova, Heidi Mocikova, Juraj Duras, Katerina Steinerova, Eva Konirova, Tomas Prochazka, Kamila Polgarova, Jitka Dlouha, Petra Blahovcova, Marek Trneny

Blood (2024) 144 (Supplement 1): 1711.

https://doi.org/10.1182/blood-2024-204795

Published: 2024

Journal Articles

Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?

Magdalena Klanova, Samuel Hricko, Michal Masar, David Salek, Prokop Vodicka, Natasa Kopalova, Petra Blahovcova, Katerina Benesova, Jozef Michalka, Jan Koren, Andrea Janikova, Marek Trneny

Blood (2023) 142 (Supplement 1): 4479.

https://doi.org/10.1182/blood-2023-178208

Published: 2023

Journal Articles

DLBCL Patients' Journey: From Symptoms to Diagnosis

Prokop Vodicka, Michal Masar, Magdalena Klanova, Katerina Benesova, Jan Koren, Pavel Klener, Petra Blahovcova, Sarka Hrabetova, Jitka Dlouha, Marek Trněný

Blood (2023) 142 (Supplement 1): 3140.

https://doi.org/10.1182/blood-2023-186207

Published: 2023

Journal Articles

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

Prokop Vodicka, Andrea Janikova, David Belada, Heidi Mocikova, Vit Prochazka, Juraj Duras, Katerina Steinerova, Vit Campr, Katerina Benesova, Samuel Hricko, Alice Sykorova, Petra Blahovcova, Radek Jaksa, Magdalena Klanova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2023-185620

Published: 2023

Journal Articles

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Heidi Mocikova, Andrea Janikova, Alice Sykorova, Vit Prochazka, Jan Pirnos, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Robert Pytlik, Petra Blahovcova, David Salek, Tomas Kozak, Veronika Bachanova, David Belada

Blood (2023) 142 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2023-180155

Published: 2023

Journal Articles

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Prokop Vodicka, Michal Masar, Magdalena Klanova, Katerina Benesova, Jan Koren, Pavel Klener, Petra Blahovcova, Jitka Dlouha, Sarka Hrabetova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4510.

https://doi.org/10.1182/blood-2023-186467

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Vitamin d and other micronutrients influence prognosis of patients with non-Hodgkin lymphoma (NHL)

Bulky disease and/or very high LDH define a high-risk LBCL subgroup within IPI 1–2, but only in younger patients

Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma

Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort

FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis

Impact of primary CNS prophylaxis in high CNS-IPI DLBCL: Analysis from the czech national lymphoma registry

Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP

Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis

Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years

Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?

PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial

Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?

DLBCL Patients' Journey: From Symptoms to Diagnosis

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only